PMID- 33464544
OWN - NLM
STAT- MEDLINE
DCOM- 20210720
LR  - 20210720
IS  - 1179-6901 (Electronic)
IS  - 1174-5886 (Print)
IS  - 1174-5886 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Mar
TI  - S100 Genes are Highly Expressed in Peripheral Leukocytes of Type 2 Diabetes 
      Mellitus Patients Treated with Dietary Therapy.
PG  - 91-101
LID - 10.1007/s40268-020-00334-z [doi]
AB  - BACKGROUND AND OBJECTIVES: We demonstrated that the mRNA induction of S100s in 
      rat peripheral leukocytes by severe hyperglycemia was reduced by inhibiting 
      postprandial hyperglycemia. Here, we compared inflammatory gene expression in 
      peripheral leukocytes between type 2 diabetes mellitus (T2DM) patients undergoing 
      dietary therapy alone and healthy volunteers, and between T2DM patients 
      undergoing dietary therapy alone and those undergoing such therapy in combination 
      with drug therapy using the alpha-glucosidase inhibitor miglitol. METHODS: T2DM 
      patients who had undertaken dietary therapy alone or in combination with drug 
      therapy using miglitol for >/= 8 weeks and healthy volunteers were subjected to a 
      meal tolerance test and glucose concentration, neutrophil elastase concentration, 
      and mRNA expression analyses of peripheral leukocytes by microarray and 
      quantitative reverse-transcription polymerase chain reaction (qRT-PCR) 
      immediately before and 180 min after a meal. RESULTS: Blood glucose 
      concentrations 60 min after a meal were lower in T2DM patients with dietary + 
      miglitol therapy than in those with dietary therapy alone. Neutrophil elastase 
      concentrations at 60 and 120 min after a meal were lower in T2DM patients with 
      dietary + miglitol therapy than in those with dietary therapy alone. Expression 
      levels of S100A8 in a fasting state and S100A6, S100A8, and S100A9 180 min after 
      a meal were higher in T2DM patients with dietary therapy alone than in healthy 
      volunteers. Expression levels of S100A12 in a fasting state and 180 min after a 
      meal were higher in T2DM patients with dietary therapy alone than in T2DM 
      patients with dietary + miglitol therapy. CONCLUSIONS: S100 genes were more 
      highly expressed in T2DM patients with dietary therapy than in healthy 
      volunteers.
FAU - Kondo, Shinnosuke
AU  - Kondo S
AD  - Department of Integrated Applied Life Science, Integrated Graduate School of 
      Medicine, Engineering, and Agricultural Sciences, University of Yamanashi, 
      Yamanashi, Japan.
FAU - Mochizuki, Kazuki
AU  - Mochizuki K
AD  - Department of Integrated Applied Life Science, Integrated Graduate School of 
      Medicine, Engineering, and Agricultural Sciences, University of Yamanashi, 
      Yamanashi, Japan. mochizukik@yamanashi.ac.jp.
AD  - Faculty of Life and Environmental Sciences, University of Yamanashi, 4-4-37 
      Takeda, Kofu, Yamanashi, 400-8510, Japan. mochizukik@yamanashi.ac.jp.
FAU - Hariya, Natsuyo
AU  - Hariya N
AD  - Department of Integrated Applied Life Science, Integrated Graduate School of 
      Medicine, Engineering, and Agricultural Sciences, University of Yamanashi, 
      Yamanashi, Japan.
AD  - Department of Nutrition, Faculty of Health and Nutrition, Yamanashi Gakuin 
      University, Kofu, Yamanashi, Japan.
FAU - Saito, Miyoko
AU  - Saito M
AD  - Naka Kinen Clinic, 745-5 Naka, Ibaraki, 311-0113, Japan.
FAU - Doguchi, Satako
AU  - Doguchi S
AD  - Naka Kinen Clinic, 745-5 Naka, Ibaraki, 311-0113, Japan.
FAU - Osonoi, Takeshi
AU  - Osonoi T
AD  - Naka Kinen Clinic, 745-5 Naka, Ibaraki, 311-0113, Japan. t-osonoi@kensei-kai.com.
LA  - eng
GR  - 17K19899/Ministry of Education, Culture, Sports, Science and Technology of Japan/
PT  - Clinical Trial
PT  - Journal Article
DEP - 20210119
PL  - New Zealand
TA  - Drugs R D
JT  - Drugs in R&D
JID - 100883647
RN  - 0 (Cytokines)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (RNA, Messenger)
RN  - 0 (S100 Proteins)
RN  - 0V5436JAQW (miglitol)
RN  - 19130-96-2 (1-Deoxynojirimycin)
SB  - IM
MH  - 1-Deoxynojirimycin/analogs & derivatives/therapeutic use
MH  - Adult
MH  - Aged
MH  - Cytokines/genetics/metabolism
MH  - Diabetes Mellitus, Type 2/*blood/*diet therapy/drug therapy
MH  - Fasting/blood
MH  - Female
MH  - Gene Expression Regulation
MH  - Hospitals, University
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Inflammation/genetics/metabolism
MH  - Leukocytes/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - RNA, Messenger/analysis
MH  - S100 Proteins/*genetics/*metabolism
PMC - PMC7937588
COIS- This study was supported by Sanwa Kagaku Kenkyusho Co., Ltd. KM and TO received 
      research grants from Sanwa Kagaku Kenkyusho Co., Ltd. The other authors have no 
      conflicts of interest.
EDAT- 2021/01/20 06:00
MHDA- 2021/07/21 06:00
PMCR- 2021/01/19
CRDT- 2021/01/19 12:17
PHST- 2020/11/30 00:00 [accepted]
PHST- 2021/01/20 06:00 [pubmed]
PHST- 2021/07/21 06:00 [medline]
PHST- 2021/01/19 12:17 [entrez]
PHST- 2021/01/19 00:00 [pmc-release]
AID - 10.1007/s40268-020-00334-z [pii]
AID - 334 [pii]
AID - 10.1007/s40268-020-00334-z [doi]
PST - ppublish
SO  - Drugs R D. 2021 Mar;21(1):91-101. doi: 10.1007/s40268-020-00334-z. Epub 2021 Jan 
      19.